Bacterial resistance to antibiotics is not a modern invention but an ancient biological trait, with resistance genes having been identified in microbiomes predating the antibiotic era by millennia. Understanding resistance requires distinguishing between intrinsic resistance, which is a fixed species-level property present before any antibiotic exposure, and acquired resistance, which emerges through mutation or horizontal gene transfer in organisms that were previously susceptible.1
Intrinsic resistance refers to the natural, inherent insensitivity of a bacterial species to an antibiotic class due to a structural or physiological property that is a constitutive feature of that organism. No selective pressure is required for intrinsic resistance to be expressed; it is present in every member of the species regardless of prior antibiotic exposure. Classic examples include the resistance of aerobic Gram-negative bacteria to vancomycin, which cannot penetrate their outer membrane lipopolysaccharide (LPS) layer, and the resistance of Pseudomonas aeruginosa to many penicillins due to limited outer membrane permeability combined with constitutively expressed efflux pumps. Similarly, Enterococcus faecalis is intrinsically resistant to all cephalosporins because penicillin-binding proteins (PBPs) in enterococci have low affinity for cephalosporins. Intrinsic resistance is predictable and stable, and susceptibility testing is generally not required or performed for drug-organism combinations known to exhibit intrinsic resistance. Clinical laboratories typically suppress these results to prevent inappropriate use of drugs that would invariably fail.
Acquired resistance arises in organisms that were previously susceptible through one of two broad mechanisms: spontaneous chromosomal mutation or acquisition of foreign deoxyribonucleic acid (DNA) carrying resistance determinants through horizontal gene transfer (HGT).1 Chromosomal mutation-based resistance arises when a random mutation in the bacterial chromosome confers survival advantage in the presence of an antibiotic. The probability that such a mutation exists in a large bacterial population before antibiotic exposure is governed by the mutation rate (typically 10-8 to 10-10 per base pair per replication for most bacteria) and the size of the population. When antibiotic concentrations are sufficient to kill susceptible bacteria but not the rare pre-existing mutant, the mutant is selectively amplified, a process called selection of pre-existing resistant variants rather than induction of new mutations. This is why the phrase "antibiotics cause resistance" is mechanistically imprecise; antibiotics select for resistance rather than cause it de novo. Prolonged subtherapeutic antibiotic concentrations are particularly prone to selecting for resistant mutants because they kill susceptible organisms while allowing partially resistant variants to survive and undergo further mutational selection.
Horizontal gene transfer is the primary driver of the modern global resistance crisis and operates through three main mechanisms: conjugation, transformation, and transduction.2 Conjugation involves direct cell-to-cell contact through a specialized appendage called a pilus, through which plasmids carrying resistance genes are transferred from donor to recipient bacteria. Plasmids are circular, extrachromosomal DNA elements that replicate independently and can carry multiple resistance genes simultaneously, enabling co-transfer of resistance to several antibiotic classes in a single event. This explains why multidrug-resistant (MDR) organisms frequently emerge suddenly with resistance to multiple structurally unrelated drug classes. Transformation involves uptake of free DNA fragments released from lysed bacteria, while transduction involves bacteriophage-mediated transfer of bacterial DNA between cells. Conjugation is the most clinically important of these mechanisms for antibiotic resistance spread.
Mobile genetic elements accelerate HGT by enabling resistance genes to move between chromosomes and plasmids and between different bacterial species. Transposons are segments of DNA that can excise from one genomic location and insert at another, carrying their cargo of resistance genes with them. Integrons are genetic platforms that capture gene cassettes through a site-specific recombination mechanism catalyzed by an integrase enzyme; class 1 integrons in particular are strongly associated with clinical antibiotic resistance and can harbor multiple resistance gene cassettes in tandem.2 Resistance islands are large chromosomal segments flanked by mobile genetic elements that carry multiple resistance genes and can be transferred en bloc between organisms. The combined action of these mobile elements explains how resistance genes identified in environmental bacteria or livestock-associated organisms can appear rapidly in human pathogens halfway around the world.
From a clinical standpoint, the distinction between intrinsic and acquired resistance has direct implications for empiric therapy selection. Intrinsic resistance is entirely predictable from species identification and does not require susceptibility testing, while acquired resistance requires laboratory testing to detect. The emergence of acquired resistance during therapy of a previously susceptible organism (secondary resistance) is a recognized clinical problem most common with rifampicin, fluoroquinolones, and linezolid when used as monotherapy for organisms with high spontaneous mutation frequencies such as Mycobacterium tuberculosis and Pseudomonas aeruginosa. Combination therapy for these organisms is specifically designed to prevent the selection of single-step mutants by ensuring that the probability of simultaneous mutations in two independent targets is too low to be biologically significant at clinically relevant bacterial population sizes.1
The mutant selection window (MSW) is the antibiotic concentration range between the minimum inhibitory concentration (MIC) of the wild-type strain and the MIC of the least susceptible single-step mutant (the mutant prevention concentration, or MPC). Drug concentrations within this window selectively amplify pre-existing resistant mutants. Subtherapeutic dosing, missed doses, and early discontinuation of therapy are common clinical scenarios that allow drug concentrations to fall into the MSW, disproportionately selecting for resistance. Pharmacodynamic dosing strategies aimed at achieving drug concentrations consistently above the MPC are a core principle of resistance prevention.
Enzymatic inactivation of antibiotics is the most prevalent and clinically consequential category of resistance mechanism worldwide. Beta-lactamases alone account for the majority of resistance to the largest antibiotic class in clinical use, and their ongoing evolution under selective pressure has driven the development of progressively broader-spectrum beta-lactams and beta-lactamase inhibitors in a perpetual cycle.3
Beta-lactamases are bacterial enzymes that hydrolyze the beta-lactam ring, which is the pharmacophore essential for penicillin-binding protein (PBP) binding and antibacterial activity of all beta-lactam antibiotics. All beta-lactamases share a common catalytic mechanism involving either a serine residue at the active site (serine beta-lactamases, comprising Ambler classes A, C, and D) or a zinc ion coordinating nucleophilic water molecules (metallo-beta-lactamases, comprising Ambler class B).3 Serine beta-lactamases form a transient acyl-enzyme intermediate that is rapidly hydrolyzed, regenerating the active enzyme and releasing the hydrolyzed (inactivated) beta-lactam. Metallo-beta-lactamases (MBLs) use a different catalytic mechanism requiring one or two zinc ions and are uniquely capable of hydrolyzing carbapenems, the agents considered last-resort therapy for many multidrug-resistant (MDR) Gram-negative infections.
The clinical classification of beta-lactamases is best understood through their substrate spectrum. Narrow-spectrum beta-lactamases (TEM-1, SHV-1) hydrolyze penicillins and early cephalosporins but not extended-spectrum cephalosporins or carbapenems. Extended-spectrum beta-lactamase (ESBL) enzymes, which arose through point mutations in narrow-spectrum enzymes that widened the active site, hydrolyze most penicillins, all cephalosporin generations including ceftriaxone and ceftazidime, and aztreonam, but not carbapenems.4 ESBL-producing organisms, predominantly Escherichia coli and Klebsiella pneumoniae, are among the most globally prevalent causes of healthcare-associated infections and are defined by their susceptibility to carbapenems and their characteristic inhibition by beta-lactamase inhibitors such as clavulanic acid, sulbactam, and tazobactam. AmpC beta-lactamases are chromosomally encoded, inducible cephalosporinases that resist inhibition by classical beta-lactamase inhibitors; organisms with inducible AmpC (the Enterobacter-Serratia-Citrobacter-Acinetobacter-Proteus-Providencia-Morganella group [ESCAPPM]: Enterobacter, Serratia, Citrobacter freundii, Acinetobacter, Proteus vulgaris, Providencia, and Morganella) can develop high-level AmpC resistance during therapy with third-generation cephalosporins through selection of derepressed mutants that constitutively overproduce the enzyme.
Carbapenemases are beta-lactamases capable of hydrolyzing carbapenems and represent the most clinically devastating enzyme class because they eliminate the last reliable oral-to-IV escalation option for many MDR Gram-negative infections.5 The major carbapenemase families include KPC (Klebsiella pneumoniae carbapenemase, class A serine enzyme, most prevalent in the United States), NDM (New Delhi metallo-beta-lactamase [MBL], class B, predominant in South Asia and now global), OXA-48 (an oxacillinase class D carbapenemase, prevalent in Europe and the Middle East) and related oxacillinases, VIM (Verona integron-encoded MBL, common in southern Europe and Pseudomonas aeruginosa), and IMP (integron-encoded MBL, prevalent in Japan and Southeast Asia). MBLs are uniquely resistant to all currently available serine-targeted beta-lactamase inhibitors (clavulanic acid, sulbactam, tazobactam, avibactam, relebactam, vaborbactam), though aztreonam retains activity against MBL-producing organisms because aztreonam is a monobactam not hydrolyzed by MBLs; when combined with avibactam (which inhibits any co-produced serine beta-lactamases), aztreonam-avibactam becomes active against many MBL producers.
Aminoglycoside-modifying enzymes (AMEs) are the primary mechanism of aminoglycoside resistance in clinical isolates and operate by chemically modifying the aminoglycoside molecule through acetylation, phosphorylation, or adenylylation (also called nucleotidylation), each catalyzed by a distinct enzyme class: acetyltransferases (AAC), phosphotransferases (APH), and nucleotidyltransferases (ANT) respectively.6 These chemical modifications reduce or abolish the ability of the aminoglycoside to bind to its target, the 16S ribosomal RNA (rRNA) of the 30S subunit. The specific aminoglycoside affected depends on the enzyme type and the position of the modification: for example, the aac(6')-Ib enzyme acetylates tobramycin and amikacin but not gentamicin, while aac(3)-I acetylates gentamicin but not amikacin, explaining why amikacin often retains activity against gentamicin-resistant organisms. Chloramphenicol acetyltransferase (CAT) enzymes inactivate chloramphenicol by acetylating its hydroxyl groups, generating a product that cannot bind the 50S ribosomal subunit; CAT-mediated resistance is encoded on plasmids, is widespread in both Gram-positive and Gram-negative organisms, and represents the primary mechanism of clinical chloramphenicol resistance.
ESBL-producing organisms may appear susceptible to extended-spectrum cephalosporins on routine disk diffusion due to inoculum effects and testing conditions that do not reflect in vivo pharmacodynamics. Clinical failures with cephalosporins in ESBL-producing bacteremia are well documented even when in vitro susceptibility is reported. Current IDSA guidelines and most international stewardship frameworks recommend carbapenems as definitive therapy for serious ESBL-producing bacteremia, reserving oral step-down to agents like trimethoprim-sulfamethoxazole (TMP-SMX) or ciprofloxacin only when susceptibility is confirmed and the infection is not life-threatening.
Target modification resistance mechanisms alter the bacterial molecule that the antibiotic binds so that the drug can no longer interact effectively with its target, while target bypass mechanisms provide an alternative pathway that circumvents the drug-inhibited step entirely. Both strategies can confer high-level resistance with a single genetic event and are responsible for some of the most clinically important resistance phenotypes, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), and macrolide-resistant streptococci.7
Penicillin-binding protein (PBP) modification is the defining mechanism of MRSA and the most clinically significant example of target modification in Gram-positive bacteria. Beta-lactam antibiotics exert their bactericidal effect by binding covalently to PBPs, the transpeptidase enzymes responsible for the final cross-linking step in peptidoglycan synthesis. MRSA resistance is mediated by the mecA gene (or the related mecC in livestock-associated MRSA), which encodes an alternative PBP designated PBP2a (also called PBP2').7 PBP2a has greatly reduced affinity for all conventional beta-lactam antibiotics due to a conformational change in its transpeptidase active site; while all other PBPs are occupied and inhibited by the drug, PBP2a continues to perform transpeptidation, enabling peptidoglycan cross-linking to proceed and the cell to survive. The mecA gene is carried on the staphylococcal cassette chromosome mec (SCCmec), a large mobile genetic element integrated into the staphylococcal chromosome; different SCCmec types are associated with hospital-acquired MRSA (HA-MRSA) and community-acquired MRSA (CA-MRSA) strains; HA-MRSA typically carries SCCmec types I through III, while CA-MRSA typically carries type IV or V. Fifth-generation cephalosporins (ceftaroline, ceftobiprole) are the first beta-lactams with sufficient affinity for PBP2a to retain activity against MRSA, exploiting an allosteric mechanism by which drug binding at a sensor domain induces a conformational change that transiently opens the active site to covalent inhibition.
Vancomycin resistance in enterococci (VRE) represents a target bypass mechanism rather than simple target modification. Vancomycin binds the D-Ala-D-Ala terminus of the pentapeptide precursor in bacterial peptidoglycan synthesis, physically blocking the transglycosylation and transpeptidation reactions. VRE resistance, primarily mediated by the vanA and vanB gene clusters, reprograms the cell wall biosynthesis pathway to produce a peptidoglycan precursor terminating in D-Ala-D-Lac (depsipeptide) instead of D-Ala-D-Ala.7 Vancomycin has approximately 1,000-fold lower affinity for the D-Ala-D-Lac terminus than for D-Ala-D-Ala, rendering it essentially ineffective. The vanA cluster, which is carried on the transposon Tn1546 and is transferable by conjugation, confers high-level resistance to both vancomycin and teicoplanin (minimum inhibitory concentrations, or MICs, often exceeding 256 mg/L for vancomycin). The vanB cluster confers variable resistance to vancomycin but not to teicoplanin, because teicoplanin does not induce vanB gene expression. The transfer of vanA from VRE to S. aureus has occurred in rare clinical isolates, producing vancomycin-resistant S. aureus (VRSA), which represents one of the most feared potential resistance developments in clinical infectious disease.
Ribosomal target modification is the predominant mechanism of resistance to macrolides, lincosamides, and streptogramin B (the macrolide-lincosamide-streptogramin B, or MLSB, phenotype), and is also relevant to tetracyclines, aminoglycosides, and oxazolidinones. The erm (erythromycin ribosome methylation) gene family encodes methyltransferases that methylate adenine residue A2058 (Escherichia coli numbering) in the 23S rRNA of the 50S ribosomal subunit.8 This single methylation event, at a position that is part of the binding site shared by macrolides, lincosamides, and streptogramin B, simultaneously confers resistance to all three drug classes. As detailed in Module 10, erm expression can be constitutive (causing resistance detectable by standard susceptibility testing) or inducible (appearing susceptible on routine testing but causing treatment failure when clindamycin is used, detectable by the D-zone test). Tetracycline resistance by ribosomal protection involves the Tet(M) and Tet(O) proteins, which are GTPases with structural similarity to elongation factors that displace tetracycline from the ribosomal A-site, allowing translation to resume in the presence of the drug. Oxazolidinone (linezolid) resistance through ribosomal mutation or methylation of G2576 (guanine residue 2576) in 23S rRNA disrupts drug binding at the peptidyl transferase center.
Fluoroquinolone resistance through target modification involves point mutations in the quinolone resistance-determining regions (QRDRs) of deoxyribonucleic acid (DNA) gyrase (GyrA/GyrB subunits) and topoisomerase IV (ParC/ParE subunits), the two enzyme complexes targeted by fluoroquinolones.9 Single mutations in the primary target (GyrA in Gram-negatives, ParC in Gram-positives) typically produce low- to moderate-level resistance; high-level resistance requires additional mutations in both primary and secondary targets. Because mutations in two independent genes must occur simultaneously for high-level resistance, fluoroquinolone monotherapy creates the paradoxical situation of imposing selection pressure for stepwise acquisition of resistance through sequential single-step mutations, each conferring incremental minimum inhibitory concentration (MIC) increases until the organism reaches clinical resistance. This explains why fluoroquinolones are prone to selecting for resistance during prolonged courses and why pharmacokinetic/pharmacodynamic (PK/PD) parameters (specifically AUC/MIC ratio) that minimize time spent in the mutant selection window are critical to resistance prevention. Oxazolidinone (linezolid) resistance through ribosomal mutation at position G2576 (guanine residue 2576) in 23S rRNA disrupts drug binding at the peptidyl transferase center.
Lipid A remodeling is the primary mechanism of polymyxin resistance in Gram-negative bacteria and involves modifications to the lipopolysaccharide molecule that reduce the electrostatic interaction between the positively charged polymyxin ring and the negatively charged phosphate groups of lipid A. The most common mechanism involves the addition of cationic groups such as phosphoethanolamine or 4-amino-4-deoxy-L-arabinose (L-Ara4N) to the phosphate groups of lipid A, reducing the net negative charge and thereby reducing polymyxin binding affinity.10 These modifications are encoded by chromosomal two-component regulatory systems (PhoPQ and PmrAB in Enterobacterales; PmrAB in Pseudomonas aeruginosa) that respond to low Mg2+ concentrations, cationic antimicrobial peptides, and other environmental signals. Of particular concern is the plasmid-mediated colistin resistance gene mcr-1 (mobile colistin resistance), first described in 2015 in China, which encodes a phosphoethanolamine transferase that modifies lipid A; mcr-1 and related variants have now been detected globally in clinical and environmental isolates, raising the prospect of transferable colistin resistance spreading to already carbapenem-resistant organisms.
The transfer of vanA-containing Tn1546 from VRE to MRSA produces VRSA, an organism resistant to both the primary agents for MRSA (vancomycin and its alternatives) and all conventional beta-lactams. Fewer than 20 confirmed VRSA cases have been reported in the United States, almost always in patients with co-colonization by both MRSA and VRE in the setting of chronic wounds or dialysis access. Active surveillance of patients with known MRSA colonization who are also at risk for VRE colonization is recommended in high-risk settings. VRSA isolates retain susceptibility to linezolid, daptomycin, and trimethoprim-sulfamethoxazole in most reported cases.
Efflux pumps and permeability barriers are physical resistance mechanisms that reduce intracellular drug concentrations by preventing entry or promoting exit of antibiotics without chemically modifying the drug itself. These mechanisms are particularly important in Gram-negative organisms, where the outer membrane provides an intrinsic permeability barrier that synergizes with efflux to produce multidrug resistance phenotypes affecting multiple structurally unrelated drug classes simultaneously.11
Bacterial efflux pumps are membrane-spanning transport proteins that actively extrude antibiotics and other toxic compounds from the bacterial cell interior, powered by ion gradients (proton motive force) or adenosine triphosphate (ATP) hydrolysis. They are organized into five major superfamilies based on structural and mechanistic characteristics: the resistance-nodulation-division (RND) family, the major facilitator superfamily (MFS), the ATP-binding cassette (ABC) family, the small multidrug resistance (SMR) family, and the multidrug and toxin extrusion (MATE) family.11 RND family pumps are the most clinically significant in Gram-negative bacteria because they span both the inner membrane and the outer membrane through a tripartite complex (an inner membrane pump, a periplasmic adapter protein, and an outer membrane channel), allowing drugs to be extruded directly into the extracellular environment rather than simply into the periplasm. The AcrAB-TolC complex in Enterobacterales (AcrB inner membrane pump, AcrA adapter, TolC outer membrane channel) and the MexAB-OprM, MexCD-OprJ, MexXY-OprM, and MexEF-OprN systems in Pseudomonas aeruginosa are the paradigmatic clinically relevant RND pumps, collectively effluxing fluoroquinolones, beta-lactams, tetracyclines, chloramphenicol, and in some cases even biocides and antiseptics.
Overexpression of efflux pumps, occurring through mutations in regulatory genes that normally repress pump expression (e.g., mexR in P. aeruginosa, acrR in E. coli), is one of the most common mechanisms of fluoroquinolone resistance development during therapy and is particularly problematic because a single regulatory mutation can simultaneously elevate resistance to multiple structurally unrelated drug classes, producing the multidrug-resistant (MDR) phenotype without any resistance gene acquisition. The Gram-positive NorA pump in S. aureus (MFS family) is a clinically relevant efflux mechanism that contributes to fluoroquinolone resistance and is also inhibited by plant-derived compounds such as reserpine, making it a target for adjunctive efflux pump inhibitor research. The MexXY-OprM system in P. aeruginosa is unique in that it can be induced by aminoglycosides, macrolides, and tetracyclines through a ribosome-sensing regulatory mechanism, creating a situation where the use of inducing antibiotics in combination may paradoxically increase resistance to those very agents.
Outer membrane permeability reduction through loss or modification of porin proteins is a critical synergistic mechanism that potentiates efflux-mediated resistance. Porins are outer membrane channel proteins through which hydrophilic antibiotics, including beta-lactams, fluoroquinolones, and carbapenems, diffuse into the periplasm of Gram-negative bacteria. Loss of specific porins through mutation or downregulation of expression reduces antibiotic entry significantly; when combined with constitutive efflux pump expression, porin loss produces synergistic resistance increases that far exceed what either mechanism alone would confer.12 In Klebsiella pneumoniae and E. coli, loss of OmpK35 and OmpK36 porins in combination with extended-spectrum beta-lactamase (ESBL) or AmpC production is a common mechanism of carbapenem resistance in organisms that do not carry a carbapenemase gene, known as non-carbapenemase carbapenem resistance. In Pseudomonas aeruginosa, loss of OprD, the specific porin that serves as the primary entry channel for imipenem, combined with MexAB-OprM overexpression, produces imipenem resistance while meropenem may retain activity, explaining the clinical phenomenon of imipenem-resistant but meropenem-susceptible P. aeruginosa.
The epidemiology of resistance gene dissemination is best understood through the lens of successful plasmid-organism combinations that have spread globally, often called high-risk clones. The sequence type 131 (ST131) lineage of E. coli, which carries CTX-M-15 (a widely prevalent ESBL enzyme) genes on IncF plasmids and is fluoroquinolone-resistant through chromosomal mutations, has disseminated globally to become the dominant cause of community-onset extended-spectrum beta-lactamase (ESBL)-producing urinary tract infection in many countries without any epidemiological link to healthcare exposure.4 Similarly, ST258 (sequence type 258) K. pneumoniae carrying KPC (Klebsiella pneumoniae carbapenemase) carbapenemases on IncFII plasmids has established itself in healthcare institutions across the Americas, Europe, and Asia. These high-risk clones combine multiple resistance mechanisms (plasmid-encoded enzymes, chromosomal pump overexpression, and porin loss) with virulence factors that facilitate persistence in the human gut and urinary tract and with fitness attributes that allow them to colonize patients without causing symptomatic infection, enabling prolonged silent transmission in healthcare settings.
The concept of the resistome, defined as the totality of all resistance genes and their precursors in both pathogenic and non-pathogenic bacteria in any given environment, has transformed understanding of where clinical resistance genes originate and where they are likely to emerge next.1 Environmental organisms, particularly soil bacteria that produce antibiotics as natural products, carry ancient resistance genes that predate human use of antibiotics by millions of years. Agricultural antibiotic use, which accounts for a substantial proportion of global antibiotic consumption, creates selection pressure in animal gut flora that accelerates the transfer and amplification of resistance genes subsequently transmissible to human pathogens through the food chain, water, and direct animal contact. The One Health framework, which recognizes the interdependence of human, animal, and environmental health in the epidemiology of resistance, has become the dominant conceptual framework for global antibiotic resistance control policy.13
Every unnecessary antibiotic prescription amplifies selection pressure for resistance in the prescriber's patient, their household contacts, and their community's shared microbiome. Antimicrobial resistance is estimated to have been directly responsible for 1.27 million deaths globally in 2019, with an additional 3.68 million deaths associated with bacterial AMR as a contributing cause.14 In the European Union, carbapenem-resistant and third-generation cephalosporin-resistant Enterobacterales alone account for tens of thousands of attributable deaths annually.15 The three foundational stewardship principles are: use antibiotics only when there is a genuine bacterial indication; choose the narrowest-spectrum agent effective for the likely pathogen; and use the shortest duration proven to be clinically effective. De-escalation from broad-spectrum empiric therapy to targeted narrow-spectrum therapy once culture and susceptibility results are available is both clinically appropriate and a direct resistance prevention intervention.
Blair JMA, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJV. Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol. 2015;13(1):42–51.
doi:10.1038/nrmicro3380Partridge SR, Kwong SM, Firth N, Jensen SO. Mobile genetic elements associated with antimicrobial resistance. Clin Microbiol Rev. 2018;31(4):e00088-17.
doi:10.1128/CMR.00088-17Bush K, Bradford PA. Beta-lactams and beta-lactamase inhibitors: an overview. Cold Spring Harb Perspect Med. 2016;6(8):a025247.
doi:10.1101/cshperspect.a025247Pitout JDD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8(3):159–166.
doi:10.1016/S1473-3099(08)70041-0van Duin D, Bonomo RA. Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation beta-lactam/beta-lactamase inhibitor combinations. Clin Infect Dis. 2016;63(2):234–241.
doi:10.1093/cid/ciw243Ramirez MS, Tolmasky ME. Aminoglycoside modifying enzymes. Drug Resist Updat. 2010;13(6):151–171.
doi:10.1016/j.drup.2010.08.003Lowy FD. Antimicrobial resistance: the example of Staphylococcus aureus. J Clin Invest. 2003;111(9):1265–1273.
doi:10.1172/JCI18535Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis. 2002;34(4):482–492.
doi:10.1086/324626Hooper DC, Jacoby GA. Mechanisms of drug resistance: quinolone resistance. Ann N Y Acad Sci. 2015;1354(1):12–31.
doi:10.1111/nyas.12830Liu Y-Y, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16(2):161–168.
doi:10.1016/S1473-3099(15)00424-7Piddock LJV. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin Microbiol Rev. 2006;19(2):382–402.
doi:10.1128/CMR.19.2.382-402.2006Nikaido H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol Mol Biol Rev. 2003;67(4):593–656.
doi:10.1128/MMBR.67.4.593-656.2003Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318–327.
doi:10.1016/S1473-3099(17)30753-3Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–655.
doi:10.1016/S0140-6736(21)02724-0Cassini A, Hogberg LD, Plachouras D, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019;19(1):56–66.
doi:10.1016/S1473-3099(18)30605-4